Warfarin has documented cannabis interaction cases. Eliquis, Xarelto, Pradaxa, aspirin, and Plavix work differently, and the evidence is much thinner than many interaction charts suggest.
“Blood thinner” covers different medications
The phrase includes anticoagulants, which slow the formation of fibrin-rich clots, and antiplatelet drugs, which make platelets less likely to stick together. They are prescribed for atrial fibrillation, blood clots, mechanical heart valves, stroke prevention, coronary disease, and other conditions. Missing doses can cause a dangerous clot, while excessive effect can cause bleeding.
Warfarin is monitored with INR
Warfarin has a narrow treatment range and many food and drug interactions. THC and CBD may inhibit CYP2C9 and other enzymes involved in warfarin metabolism, potentially raising INR and bleeding risk.
Direct oral anticoagulants are different
Eliquis, Xarelto, Pradaxa, and Savaysa use fixed doses and are not routinely monitored with INR. Their labels warn about strong P-glycoprotein or CYP3A4 interactions, depending on the drug.
Aspirin and Plavix affect platelets
These are antiplatelet medicines, not anticoagulants. CBD can inhibit CYP2C19 in laboratory studies, which raises a theoretical concern because clopidogrel must be activated through CYP2C19. Clinical cannabis outcome data are lacking.
Heparin products are injected
Heparin and enoxaparin do not depend on the same liver pathways as warfarin or apixaban. Cannabis may still increase fall, injury, judgment, or adherence risks while the medicine makes bleeding easier.
What the evidence says for each blood thinner
| Medication | Known or suspected cannabis issue | Practical response |
|---|---|---|
| Warfarin or Coumadin | Multiple reports of elevated INR after THC or CBD. CYP2C9 inhibition is a proposed mechanism. Both dose and route may matter. | Contact the anticoagulation clinic before a change and ask whether INR should be checked sooner or more often. |
| Eliquis or apixaban | No published clinical cannabinoid interaction evidence in the 2023 systematic review. Apixaban is affected by strong combined P-gp and CYP3A4 inhibitors. | Do not infer safety from the lack of reports. Ask a pharmacist, especially with high-dose oral CBD or several interacting medicines. |
| Xarelto or rivaroxaban | Clinical cannabis interaction data are absent. Rivaroxaban uses P-gp and CYP3A4 pathways, creating a theoretical concern. | Review every prescription, supplement, and cannabis product. There is no routine INR test that rules out an interaction. |
| Pradaxa or dabigatran | P-gp is important to absorption. A cannabinoid effect is theoretically possible, but human interaction evidence is lacking. | Ask a pharmacist rather than applying warfarin advice. Kidney function and other medicines also matter. |
| Savaysa or edoxaban | Also depends on P-gp. Direct clinical cannabis data have not established an interaction. | Do not stop or adjust the dose. Report changes in cannabis use to the prescriber. |
| Aspirin | Laboratory platelet studies are old and conflicting, and they do not establish the effect of dispensary cannabis in patients. | Avoid adding other bleeding-risk medicines unless approved. Report black stool, vomiting blood, or unusual bleeding. |
| Plavix or clopidogrel | CBD inhibition of CYP2C19 could theoretically reduce clopidogrel activation, but clinical outcome evidence is missing. | Ask a cardiology pharmacist before using concentrated CBD. Reduced antiplatelet effect could increase clot risk rather than bleeding. |
How cannabis could change bleeding or clotting risk
Slower warfarin metabolism
S-warfarin is processed mainly through CYP2C9. THC and CBD inhibit this enzyme in laboratory studies. Slower clearance can raise warfarin exposure and INR, although real products and doses vary.
P-gp and CYP3A4 pathways
Some newer anticoagulants depend on the P-glycoprotein transporter, CYP3A4, or both. Cannabinoids can affect these pathways in laboratory work, but predicted interactions have not been confirmed in patients.
Falls and injuries
THC-related dizziness, poor coordination, slower reaction time, or fainting can cause trauma. A minor fall becomes more concerning when anticoagulation increases the chance of internal or brain bleeding.
Platelet effects remain unclear
Laboratory studies have reported both inhibited and activated platelet responses under different conditions. Those experiments do not justify telling patients that cannabis “thins” or “thickens” blood.
Smoking creates another variable
Combustion smoke contains chemicals that can affect enzymes and cardiovascular function. Switching abruptly between smoking, edibles, and concentrated oils changes exposure in ways an anticoagulation team needs to know.
Consistency matters
A stable low exposure may behave differently from a sudden increase. Several warfarin cases followed starting CBD, increasing THC, or changing regular cannabis use.
Smoking, vaping, edibles, and CBD products
Smoking flower
Inhaled THC acts quickly and adds smoke exposure, dizziness, and impaired coordination. Warfarin case literature includes smoked cannabis, but there is no dose-response trial.
Vaping or dabbing
Concentrates can deliver a large THC dose rapidly. A stronger high increases fall and injury risk, while unregulated products make the true cannabinoid dose difficult to report.
Edibles
Edibles avoid smoke but can deliver sustained cannabinoid exposure for many hours. One case described an INR of 7.2 after a month of edible cannabis plus smoking in a person previously stable on warfarin.
CBD oils and prescriptions
High-dose oral CBD has the clearest reported warfarin dose interactions. Over-the-counter labels may be inaccurate, and “CBD only” does not mean interaction free.
Changing the route does not automatically solve the medication problem. What matters includes THC and CBD dose, frequency, regularity, interacting medicines, liver or kidney function, age, fall risk, and the specific blood thinner.
What the studies and reports found
Six of seven warfarin cases had increased anticoagulation
Researchers screened 519 unique citations and found seven warfarin case reports. Six described elevated INR, with maximum reported changes ranging from 0.4 to 9.61. One report involved bleeding that required hospitalization and reversal. Doses were often unknown or extremely high, and the authors rated the evidence very low quality. They found no clinical interaction evidence for other anticoagulants. Read the review.
Recreational cannabis was followed by an INR of 4.6
A 27-year-old man taking warfarin for a mechanical heart valve developed an INR of 4.6 after cannabis use. The review also identified episodes with INR above 10 and bleeding, plus an Epidiolex case requiring a 30 percent warfarin reduction. Only three eligible publications were available. Read the report.
Warfarin dose fell nearly 20 percent after CBD initiation
A patient receiving FDA-approved cannabidiol had INR monitored during CBD titration and ultimately required a nearly 20 percent weekly warfarin reduction. The authors recommended frequent INR checks when prescription CBD is started. This does not establish the effect of a low-dose retail gummy. Read the report.
A previously stable INR rose to 7.2
A 35-year-old taking 10 mg warfarin daily had been stable for years before INR rose after a month of edible cannabis and smoking. No bleeding was reported. INR fell after cannabis was discontinued and warfarin was adjusted, making the interaction probable but not definitively proven. Read the report.
One patient had no major INR change
An 85-year-old used a low-dose oromucosal product containing THC and CBD while taking warfarin and had minimal INR fluctuation over about a year. The contrasting result suggests that dose and route may influence risk, but one stable case cannot define a safe threshold. Read the report.
Cannabis-infused water coincided with elevated INR
Three patients in Thailand consumed water boiled with cannabis flower while taking warfarin. Reported INR values ranged from 3.49 to 4.92 without bleeding and returned to therapeutic ranges after cannabis stopped. The preparation was not standardized, so the exact THC and CBD exposure was uncertain. Read the reports.
Eliquis interaction rules focus on strong P-gp and CYP3A4 modifiers
The Eliquis label says combined strong P-gp and CYP3A4 inhibitors increase apixaban exposure and bleeding risk. Cannabis is not listed as a clinically measured interaction. Laboratory predictions about cannabinoids should therefore prompt a medication review, not a claim that a specific cannabis dose changes Eliquis levels. Read the FDA label.
Bleeding signs that need attention
Call the prescribing team promptly
Report frequent nosebleeds, bleeding gums, unusually heavy menstrual bleeding, unexplained bruises, prolonged bleeding from small cuts, red or brown urine, or a significant change in cannabis use.
Internal bleeding may be hidden
Black tarry stool, red stool, vomiting blood or material that looks like coffee grounds, severe abdominal or back pain, increasing weakness, or unusual pallor need urgent evaluation.
Clot warning signs matter too. Sudden shortness of breath, chest pain, coughing blood, one swollen painful leg, or stroke symptoms can mean the medicine is not providing enough protection. Cannabis should never be used as a substitute for an anticoagulant or antiplatelet drug.
A practical safety plan
- Do not stop the blood thinner. Missing doses can cause stroke, pulmonary embolism, valve thrombosis, or another serious clot.
- Identify the exact medicine. “Blood thinner” is not enough. Share the drug, dose, reason for treatment, kidney or liver problems, and all antiplatelet medicines.
- Report the cannabis accurately. Include route, THC percentage, CBD milligrams, serving size, frequency, and any planned increase or decrease.
- Ask about monitoring before the change. Warfarin patients may need an earlier INR. Direct oral anticoagulants do not use INR, so a pharmacist review is especially important.
- Avoid adding bleeding-risk medicines. Ibuprofen, naproxen, aspirin, alcohol, supplements, and other prescriptions may compound risk. Use only what your clinician approves.
- Reduce fall and injury risk. Avoid driving, ladders, power tools, contact sports, or high-potency cannabis while impaired.
- Tell every procedural clinician. The surgeon, dentist, anesthesiologist, and anticoagulation team need both medication and cannabis details. See our cannabis before surgery guide.
Blood pressure and faintness can also affect fall risk. Read how cannabis changes blood pressure. If an infection medicine is added, our cannabis and antibiotics guide explains why the exact prescription matters.
Frequently asked questions
Can you smoke weed while taking warfarin?
Warfarin has the strongest evidence of a potential interaction. Several reports describe elevated INR after THC or CBD. Contact the anticoagulation clinic before using cannabis or changing an established pattern.
Can you smoke weed while taking Eliquis?
No clinical cannabinoid interaction was found in the 2023 systematic review, but that does not prove safety. Eliquis depends on P-gp and CYP3A4 pathways and has serious bleeding risks. Ask a pharmacist about your product and other medicines.
What about Xarelto and weed?
Direct human interaction data are lacking. Xarelto uses P-gp and CYP3A4 pathways, so concentrated oral cannabinoids create a theoretical concern. Do not change the Xarelto dose.
Does cannabis raise INR?
Case reports show INR increases in many warfarin patients after THC or CBD, but not every case. Cannabis does not create an interpretable INR change in people taking Eliquis, Xarelto, or other medicines that are not monitored with INR.
Is CBD safe with blood thinners?
Not automatically. High-dose CBD has been linked to clinically important warfarin interactions and can inhibit several drug-processing enzymes. Retail CBD strength and purity may also differ from the label.
Are edibles safer than smoking on a blood thinner?
They avoid smoke, but they do not remove medication interactions, prolonged impairment, falls, or bleeding after injury. A published warfarin case involved both edibles and smoked cannabis.
Can weed make you bleed more?
It may increase warfarin effect in some patients, but research does not prove that cannabis universally “thins the blood.” Platelet experiments are conflicting, and clinical evidence for most anticoagulants is absent.
Can I take aspirin and smoke weed?
Aspirin affects platelets and increases bleeding risk. Cannabis interaction data are insufficient. Ask a pharmacist, especially if you also take an anticoagulant, clopidogrel, an NSAID, or drink alcohol.
Should I stop cannabis before an INR test?
Do not make an abrupt change just to influence a test without speaking to the anticoagulation clinic. Tell them what you have been using and follow their instructions so the result reflects an understood pattern.
Should I stop my blood thinner if I already smoked?
No. Stopping can cause a dangerous clot. Contact the prescribing team for advice and get urgent help for major bleeding, head injury, stroke signs, chest pain, fainting, or severe shortness of breath.
Sources
- Systematic review of cannabinoid and anticoagulant interactions
- Warfarin and cannabis case report and mini-review
- Warfarin dose adjustment after cannabidiol
- Inhaled and edible cannabis with warfarin
- Low-dose medical cannabis and stable warfarin case
- Cannabis-infused water and warfarin case series
- Systematic review of cannabinoid interactions with narrow-therapeutic-index drugs
- FDA Eliquis prescribing information
Medical note: This guide provides general education and cannot determine whether cannabis is safe with your anticoagulant or antiplatelet medicine. Do not start, stop, skip, or adjust a blood thinner because of a web article. Ask the prescribing clinician or pharmacist.
Chris Garcia, Owner and CEO
August 29, 2026
How this page is prepared: Plenny uses linked research and other relevant sources for educational explanations, and product details and batch COAs where relevant. General strain, flavor, and effect descriptions are not guarantees.
Commercial transparency: Plenny sells products discussed on this website. Educational pages are not medical or legal advice, and content is not medically reviewed unless a named licensed reviewer is shown.